An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Study Identifier
M19-388
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
2022-501522-38-00
For general inquiries, please contact
Recruitment Complete
Sign up for trial alerts

Study Details

Medical Condition
  • Blood Cancer - Chronic Lymphocytic Leukemia (CLL)
  • Blood Cancer - Acute Myeloid Leukemia (AML)
  • Blood Cancer - Multiple Myeloma
  • Blood Cancer - Non-Hodgkin's Lymphoma (General)
  • Blood Cancer - Acute Lymphoblastic Leukemia (ALL)
  • Cancer - Other
  • Study Drug
  • Venetoclax
  • Phase
    Phase 3
    Sex
    Female & Male
    Age
    N/A

    Protocol Summary

    The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.

    Study Locations

    Location
    Status
    Location
    University of Arizona Cancer Center - Tucson /ID# 210548
    Tucson, Arizona, United States, 85724
    Status
    Not applicable
    Location
    UCLA Santa Monica Hematology Oncology /ID# 210551
    Los Angeles, California, United States, 90095
    Status
    Not applicable
    Location
    Ingalls Memorial Hosp /ID# 210553
    Harvey, Illinois, United States, 60426
    Status
    Not applicable
    Location
    Dana-Farber Cancer Institute /ID# 215360
    Boston, Massachusetts, United States, 02215
    Status
    Not applicable
    Location
    University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 231132
    Ann Arbor, Michigan, United States, 48109
    Status
    Not applicable
    Location
    Dartmouth-Hitchcock Medical Center /ID# 210555
    Lebanon, New Hampshire, United States, 03756
    Status
    Not applicable
    Showing {first} - {last} of {total} Results